DelMar Pharmaceuticals, Inc. – "Optimism and Opportunity as we Initiate Clinical Trials for MGMT-unmethylated GBM Patients at MD Anderson"

DelMar Pharmaceuticals (NASDAQ:DMPI) today published a new blog post on The Chairman’s Blog, written by the Company’s Chief Executive Officer, Jeffrey Bacha. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
In his blog, Mr. Bacha reflects on DelMar’s recently announced Phase 2 trial with MD Anderson Cancer Center for MGMT-unmethylated glioblastoma multiforme (GBM) patients. He writes that this new trial is a keystone in the Company’s strategy to expand the development of VAL-083 to “have the greatest disease impact, the greatest benefit to patients, and, ultimately, the greatest benefit to shareholder value.” Read the full blog post from Mr. Bacha on TheChairmansBlog.com (https://www.thechairmansblog.com/delmar-pharmaceuticals/jeffrey-bacha/optimism-and-opportunity-as-we-initiate-clinical-trials-for-mgmt-unmethylated-gbm-patients-at-md-anderson-2/).
About DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company’s lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.
About TheChairmansBlog.com
TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment (www.thechairmansblog.com).
Click here to connect with DelMar Pharmaceuticals (NASDAQ:DMPI) to receive an Investor Presentation.